Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Devgen, Sanofi, Venganza, and More


Title: Method of Treating Malignant Mesothelioma

Patent Number: 8,771,688

Filed: Feb. 7, 2012

Lead Inventor: Chikao Morimoto, University of Tokyo

Title: Method and Constructs for Delivering Double-stranded RNA to Pest Organisms

Patent Number: 8,772,254

Filed: Oct. 25, 2005

Lead Inventor: Thierry Bogaert, Devgen (Syngenta)

Title: Cell-transfecting Formulations of Small Interfering RNA-related Compositions and Methods of Making and Use

Patent Number: 8,772,255

Filed: March 21, 2008

Lead Inventor: Timothy Burkoth, Novartis Vaccines and Diagnostics

Title: Single-walled Carbon Nanotube/siRNA Complexes and Methods Related Thereto

Patent Number: 8,772,258

Filed: July 1, 2011

Lead Inventor: D. Lynn Kirkpatrick, Ensysce Biosciences

Title: Preventive or Therapeutic Agent for Fibrosis

Patent Number: 8,772,262

Filed: Oct. 14, 2011

Lead Inventor: Esteban Gabazza, Otsuka Pharmaceutical

Title: Synthetic Double-stranded Oligonucleotides for Specific Inhibiting on Gene Expression

Patent Number: 8,772,469

Filed: July 11, 2002

Lead Inventor: Eugen Uhlmann, Sanofi

Title: Compositions and Methods for Treatment of Prostate and Other Cancers

Patent Number: 8,772,470

Filed: Nov. 30, 2007

Lead Inventor: Martin Gleave, University of British Columbia

Title: Targeted Delivery of siRNA

Patent Number: 8,772,471

Filed: Jan. 25, 2008

Lead Inventor: Premlata Shankar, Immune Disease Institute (Harvard Medical School)

Title: siRNA Conjugate and Preparation Method Thereof

Patent Number: 8,772,472

Filed: Sept. 13, 2012

Lead Inventor: Bo Ram Han, Bioneer

Title: Methods and Materials for Conferring Resistance to Pests and Pathogens of Plants

Patent Number: 8,772,572

Filed: April 22, 2013

Inventor: Charles Niblett, Venganza

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.